A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma.

Trial Profile

A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Denosumab (Primary) ; Zoledronic acid
  • Indications Bone metastases; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
  • Focus Registrational; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 11 Oct 2016 Results of post-hoc analysis analyzing symptomatic skeletal events (SSEs) versus skeletal-related events (SREs) from patients with advanced cancer and bone metastases (n=1597) presented at the 41st European Society for Medical Oncology Congress.
    • 12 Jun 2014 Subgroup analysis results for primary endpoint (time to SRE) published in the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 24 Oct 2012 Planned number of patients changed from 1690 to 1779.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top